8-K: ORIC Pharmaceuticals Announces First Quarter 2025 Financial Results and Provides Operational Update

ORIC Pharmaceuticals reports its Q1 2025 financial results, highlighting progress in clinical development plans, extended cash runway into 2027, and key corporate milestones.

Summary

• ORIC Pharmaceuticals announced its first quarter 2025 financial results and provided operational updates.
• The company reported encouraging early safety and efficacy data for ORIC-944 in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC).
• A clinical trial collaboration and supply agreement with Johnson & Johnson was initiated to evaluate ORIC-114 in combination with subcutaneous amivantamab for first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations.
• ORIC anticipates reporting five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months.
• The company expects to initiate registrational trials for both programs in 2026.
• Cash and investments totaled approximately $224 million as of March 31, 2025, expected to fund the operating plan into 2027.
• Research and development expenses were $24.6 million for the quarter, compared to $22.0 million for the same period in 2024.
• General and administrative expenses were $8.1 million, compared to $7.0 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the clinical progress, extended cash runway, and collaboration with Johnson & Johnson, offset by increased operating expenses and net loss.

Positives

• ORIC-944 shows encouraging early safety and efficacy data in combination with apalutamide for mCRPC.
• The collaboration with Johnson & Johnson to evaluate ORIC-114 with amivantamab in NSCLC is a positive development.
• The company's cash runway has been extended into 2027.
• ORIC is on track to initiate a Phase 3 trial of ORIC-944 in mCRPC in the first half of 2026.
• Registrational development of ORIC-114 in first-line NSCLC is expected to begin later in 2026.

Negatives

• The company reported a net loss of $30.0 million for the quarter ended March 31, 2025, compared to a net loss of $25.0 million for the same period in 2024.
• Research and development expenses increased to $24.6 million from $22.0 million year-over-year.
• General and administrative expenses increased to $8.1 million from $7.0 million year-over-year.

Risks

• Clinical trial outcomes may materially change as patient enrollment continues or more patient data becomes available.
• The company's ability to obtain approvals for and commercialize its product candidates is subject to risks.
• Changes in ORIC's plans to develop and commercialize its product candidates could impact future results.
• The company's reliance on third parties, including contract manufacturers and contract research organizations, poses a risk.
• Competition in the industry in which ORIC operates could impact its success.

Future Outlook

ORIC expects to share multiple clinical data updates across both ORIC-944 and ORIC-114 programs over the next fifteen months and remains on track to initiate the first Phase 3 trial of ORIC-944 in mCRPC in the first half of 2026, with registrational development of ORIC-114 in first-line NSCLC expected to begin later that year.

Management Comments

• In the first quarter, we made significant progress across our pipeline, announced focused registrational development plans for our two lead programs, extended our cash runway, and accelerated key corporate milestones, stated Jacob M. Chacko, M.D., president and chief executive officer.
• Looking ahead, we expect to share multiple clinical data updates across both programs over the next fifteen months.

Industry Context

ORIC's focus on overcoming resistance in cancer aligns with the broader industry trend towards precision medicine and targeted therapies. The collaboration with Johnson & Johnson reflects the increasing importance of combination therapies in oncology.

Comparison to Industry Standards

• ORIC's cash runway extending into 2027 provides a competitive advantage compared to other clinical-stage biopharmaceutical companies that may need to raise additional capital sooner.
• The collaboration with Johnson & Johnson to evaluate ORIC-114 with amivantamab in NSCLC is similar to other partnerships between biotech and large pharmaceutical companies to develop novel combination therapies.
• ORIC's focus on developing treatments that address mechanisms of therapeutic resistance is in line with industry efforts to improve outcomes for cancer patients who develop resistance to existing therapies.

Stakeholder Impact

• Shareholders may be positively impacted by the clinical progress and extended cash runway.
• Employees may benefit from the company's continued growth and development.
• Patients may benefit from the development of new cancer treatments.
• The collaboration with Johnson & Johnson could benefit both companies.

Next Steps

• ORIC anticipates reporting combination dose escalation data with AR inhibitors for ORIC-944 in 1H 2025.
• ORIC anticipates reporting updated combination dose escalation data with AR inhibitors for ORIC-944 in 2H 2025.
• ORIC anticipates reporting 1L EGFR exon 20, 2L EGFR exon 20, 2L+ HER2 exon 20 and 2L+ EGFR atypical data for ORIC-114 in 2H 2025.
• ORIC anticipates reporting combination dose optimization data with AR inhibitor(s) for ORIC-944 in 4Q 2025 / 1Q 2026.
• ORIC anticipates reporting 1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical data for ORIC-114 in Mid-2026.
• ORIC expects to initiate the first Phase 3 trial of ORIC-944 in mCRPC in the first half of 2026.
• ORIC expects to begin registrational development of ORIC-114 in first-line NSCLC later in 2026.

Key Dates

Keywords

ORIC Pharmaceuticals, ORIC-944, ORIC-114, mCRPC, NSCLC, EGFR, HER2, Clinical Trials, Financial Results, Oncology, Amivantamab, Johnson & Johnson